Therapeutic Strategies in Lipid Disorders

AM Tonkin

Therapeutic Strategies in Lipid Disorders
Preview this ebook

Product details

Published27th April 2009
Print ISBN9781846920349
PublisherClinical Publishing
Subjects:Cardiovascular medicine, Endocrinology
Thema 1.1:MJD, MJG
123Library ID:1866

eBook Overview

Lipid disorders are now recognised as a diverse group of diseases that together represent one of the foremost risk factors for cardiovascular disease in general. Frequently present in association with other chronic illnesses such as hypertension, diabetes, and obesity, lipid disorders are a key therapeutic target for clinicians. This book examines the causes and consequences of lipid disorders, and the treatments available. Special chapters are dedicated to the associations between lipid disorders and other conditions, for example cerebrovascular disease and heart failure, as well as the wider applications for lipid-lowering agents in the management of co-morbidities. The book concludes with a review of novel lipid-modifying agents, emerging diagnostic technologies such as intravascular ultrasound, and the use of biomarkers as risk predictors.

Search inside this book:

Table of Contents

Editorand Contributors6
Chapter 1: A global view of cardiovascular risk factors10
Chapter 2: Low-density lipoprotein cholesterol as a therapeutic target23
Chapter 3: High-density lipoprotein as a therapeutic target36
Chapter 4: Apolipoprotein B in the therapy of atherogenic dyslipoproteinaemias49
Chapter 5: Management of coronary heart disease patients64
Chapter 6: Stroke and transient ischaemic attack prevention81
Chapter 7: Diabetes and the metabolic syndrome90
Chapter 8: Hypertension109
Chapter 9: Treatment of familial hypercholesterolaemia119
Chapter 10: Lipid lowering in chronic kidney disease137
Chapter 11: Statins and heart failure145
Chapter 12: Absolute risk assessment in the general population157
Chapter 13: Pleiotropic effects of statins and potential new indications179
Chapter 14: The role of imaging endpoints in clinical trials197
Chapter 15: Biomarkers in cardiovascular disease212
Chapter 16: Novel lipid-modifying agents227
Chapter 17: The enhanced evidence base and translation into improved outcomes245